The emerging fields of suicide gene therapy and virotherapy

Trends in Molecular Medicine

Volumn 8, Issue 4, 2002, Pages S68-S73

  Kirn, David ^a   Niculescu Duvaz, Ion ^b   Hallden, Gunnel ^a   Springer, Caroline J ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 73 T; ADENOVIRUS VECTOR; ALANINE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE G2; CEPHEM DERIVATIVE; CN 706; CN 787; CYTARABINE; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; G 207; H 1; HYDROGEN PEROXIDE; IRINOTECAN; MERCAPTOPURINE; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; ONYX 015; OXAZAPHOSPHORINE DERIVATIVE; PARACETAMOL; PRODRUG; PURINE NUCLEOSIDE; PYRIMIDINE DERIVATIVE; REOLYSIN; SELENOMETHIONINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 2767;

ASTHENIA; CANCER; CANCER CELL; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; FEVER; FLU LIKE SYNDROME; GENE DELIVERY SYSTEM; GENE MUTATION; GENETIC ENGINEERING; HUMAN; LIVER TOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RIGOR; SUICIDE GENE THERAPY; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; PRODRUGS; RETROVIRIDAE; VACCINIA VIRUS;

ADENOVIRIDAE;

EID: 0036218215     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02318-3     Document Type: Review

References (47)

1. Advances in cancer gene therapy
2. Gene therapy for cancer: What have we done and where are we going?
3. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme prodrugs therapies
4. Gene-directed enzyme prodrug therapy
5. Improving enzymes for gene therapy
6. Patent property of prodrug involving gene therapy (1996-1999)
7. Prodrug-activating systems in suicide gene therapy
8. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
9. Purification and properties of carboxypeptidase G2 Pseudonomas sp strain RS-16
10. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination
11. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy
12. Regressions of established breast cancer xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect
13. Replication-selective micro-organisms: Fighting cancer with targeted germ warfare
14. Two regions of the adenovirus early region 1A proteins are required for transformation
15. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
16. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
17. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
18. Adenovirus E1A-p105 (Rb) protein interactions play a direct role in the initiation but not the maintenance of the rodent cell transformed phenotype
19. Cancer cell cycles
20. The properties of p53 proteins selected for the loss of suppression of transformation
21. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
22. Experimental therapy of human glioma by means of a genetically engineered virus mutant
23. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
24. Cellular targets for transformation by the adenovirus E1A proteins
25. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations
26. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy
27. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
28. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
29. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
30. p53 mutations in human cancers
31. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
32. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
33. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication
34. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
35. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?
36. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer
37. Adenovirus 2 Ip+ locus codes for a 19 kd tumor antigen that plays an essential role in cell transformation
38. Deletion of the adenoviral E1B-19kD gene enhances tumor cell killing of a replicating adenoviral vector
39. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells
40. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
41. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
42. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
43. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
44. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
45. Targeted gene delivery by tropism-modified adenoviral vectors
46. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependent on sequencing but not p53 functional status or route of administration